Gini Fleming to Recombinant Proteins
This is a "connection" page, showing publications Gini Fleming has written about Recombinant Proteins.
Connection Strength
0.217
-
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004 Aug; 15(8):1173-8.
Score: 0.053
-
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 01; 22(11):2159-66.
Score: 0.053
-
Re: Response of aleukemic granulocytic sarcoma to all-trans-retinoic acid plus interferon alfa-2a. J Natl Cancer Inst. 1997 Jan 15; 89(2):172-3.
Score: 0.032
-
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
Score: 0.031
-
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. Cancer. 1996 Jun 01; 77(11):2308-12.
Score: 0.030
-
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant. 2001 Apr; 27(7):677-81.
Score: 0.011
-
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
Score: 0.007